2021 Revenues ($USD) : $19,736,820,000
2021 Revenues (foreign currencies) : € 17,313,000,000
2021 R&D spend : $2,077,080,000
2021 Number of Employees : 77,000
Fiscal Year End : 12/31/2020
Key People : Frans van Houten, CEO; Sophie Bechu, EVP, chief operations officer; Abhijit Bhattacharya, EVP, CFO; Marnix van Ginneken, EVP, chief legal officer; Andy Ho, EVP, chief market leader, Philips Greater China; Roy Jakobs, EVP, chief business leader, connected care; Deeptha Khanna, EVP, chief business leader, personal health; Bert van Meurs, EVP, chief business leader, image guided therapy; Edwin Paalvast, EVP, chief, international markets; Shez Partovi, EVP, chief innovation and strategy officer; Vitor Rocha, EVP, chief market leader, Philips North America; Daniela Seabrook, EVP, chief human resources officer; Kees Wesdorp, EVP, chief business leader, precision diagnostics.

About the company: Royal Philips began as a light bulb maker when it was first founded in the Netherlands in 1891, but it shifted its focus to healthcare over the past decade, spinning off its lighting business in 2016. Philips’ offerings include a wide array of imaging systems and diagnostic products. The company produces respiratory products for diseases such as sleep apnea, although recent recalls have knocked it out of that market for the foreseeable future as the company also faces lawsuits and congressional scrutiny over issues with its sleep devices. Philips bookended this year with two major acquisitions to make a big play in the cardiac monitoring space. The company paid $2.8 billion for BioTelemetry and its diagnostics and monitors for heart rhythm disorders, then bought Cardiologs and its artificial intelligence (AI)-based technology for cardiac diagnostics for an undisclosed amount.  –SW